Módulo 4 – Curso pós-graduado – VIH e Envelhecimento

Renal Disease in HIV Infected and HIV/HCV Co-infected patients

Gestão clínica da doença renal em doentes coinfetados por VIH/VHC

Bibliografia

  1. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008; 109: S1-99.
  2. Corouge M, ValletPichard A, Pol HCV and the kidney. Liver Int 2016; 36: 28-33.
  3. Lee M-H, Yang HI, Lu SN, et Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012; 206: 469-77.
  4. Park H, Adeyemi A, Henry L, et A metaanalytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. J Viral Hepat 2015; 22: 897-905.
  5. Molnar MZ, Alhourani HM, Wall BM, et al. Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology 2015; 61: 1495-1502.
  6. AASLD/IDSA HCV Guidance Panel. Hepatitis C Guidance: AASLD-IDSA Recommendations for testing, managing, and treating adults infected with hep- atitis C virus. Hepatology 2015; 62:932–54;
  7. European Association for the Study of the EASL Recommendations on treatment of Hepatitis C 2015. J Hepatol 2015; 63: 199–236.
  8. Vierling Jm, Lawitz E, Reddy KR, et RUBY-I: safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in adults with genotype 1 chronic hepatitis C virus (HCV) infection with severe renal impairment or end-stage renal disease. AASLD Liver Meeting. Boston, November 11-15, 2016.Abstract 886.
  9. Gane RJ, Solà R, Cohen E, et RUBY-II: Efficacy and safety of a ribavirin-free ombitasvir/paritaprevir/ritonavir ± dasabuvir regimen in patients with severe renal impairment or end-stage renal disease and HCV genotypes 1a or 4 infection. AASLD Liver Meeting. Boston, November 11-15, 2016.Abstract 935.
  10. Herbst DA Jr, Reddy KR. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus Expert Opin Investig Drugs 2013; 22: 527-36.
  11. Resumo das Características do Medicamento. Sofosbuvir/Sovaldi – EMEA/ H/C/002798 -A20/0029 (disponível em http://www.ema.europa.eu/ema/).
  12. Kirby B, Gordi T, Symonds WT, et Population pharmacokinetics of sofosbuvir and its major metabolite (GS-331007) in healthy and HCV-infected adult subjects. AASLD Liver Meeting 2013. Washington DC, November 1-4, 2013. Abstract 1106.
  13. Pockros PJ, Reddy KR, Mantry PS, et Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 2016; 150: 1590-8.
  14. Roth D, Nelson DR, Bruchfels A, et Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infec- tion and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. The Lancet. 2015; 386: 1537-45.
  15. Reddy KR, Roth D, Bruchfels A, et Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C Virus infection and pre-existing renal dis- ease. AASLD Liver Meeting. Boston, November 11-15, 2016.
Logo MSD Termos de utilização | Política de Privacidade | Sobre a MSD Copyright © 2018 Todos os direitos reservados. Merck Sharp & Dohme Corp.,uma subsidiária da Merck & Co., Inc. Kenilworth, NJ, USA, conhecida fora dos EUA e Canadá como MSD. Os conteúdos disponibilizados nesta página Web são informação de carácter geral e não substituem em nenhum caso as consultas, tratamentos ou as recomendações do seu médico. INFC-1273571-0000 11/2018